No need for a 3-year trial because patients won't be living that long. These are patients with advanced inoperable cancer that has stopped responding to standard of care. A 2- or 3-month gain in overall survival would be a major win.
All I can say is that this is not a short term investment or stock. You won't be seeing any major PPS changes until trials start and after they finish.
Never was a short term PPS stock so I don't see what the problem is. Patience is where it's at.
News 
Market Data 
Discover 
